## CTSH: Cognizant Technology Solutions  - XLK: Technology

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.3% in lower entry zone (3.0-6.0%), top quartile (82nd pct) cross-sectional ranking. Short-term MRS_5 (0.8%) confirms momentum alignment. Outperforming sector by 3.6%. Caution: overbought RSI (78).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($80.05)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Novanta (Nasdaq: NOVT) to present at J.P. Morgan 44th healthcare conf.**
- Source: Stock Titan | 20251215T160852 | Neutral | Relevance: 63%
- Novanta Inc. (Nasdaq: NOVT) announced that its Chair & Chief Executive Officer, Matthijs Glastra, and Chief Financial Officer, Robert Buckley, are scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on Wednesday, January 14, 2026, in San Francisco, California. Novanta is a global supplier of core technology solutions for medical and advanced industrial original equipment manufacturers. The company's shares are traded on Nasdaq under the symbol “NOVT.”

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | UBS | $82 | $78 | +5% |
| 2025-11-21 | William Blair | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | UBS | main | Neutral |
| 2025-11-21 | William Blair | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($0.00M) |
| Sells | 14 ($1.22M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.8%)
- Blackrock Inc.: 10.5% (-0.2%)
- JPMORGAN CHASE & CO: 8.2% (+108.3%)
- State Street Corpora: 5.2% (-0.9%)
- Pzena Investment Man: 3.7% (+1.5%)

### Key Risks

1. Elevated short interest (8.1%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.48 suggests fair value with growth premium. Forward P/E 14.9x stretched relative to 7% growth. Quality metrics strong (ROA 10%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.35), $1.2B free cash flow. Analyst sentiment positive (1 raises, avg +5%). Insider selling cluster ($1.2M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.8B |
| Beta | 0.97 |
| 52W Range | $65.15 - $90.82 |
| Short Interest | 8.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.48 |
| Forward P/E | 14.9 |
| Current P/E | 15.9 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.5% over 5 days). Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 82nd percentile. MRS_5 at 0.8% confirms short-term momentum alignment. Outperforming sector by 3.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 78, risk of mean reversion. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.30% (CS: 82) | Strong |
| RSI_14 | 78.3 | Overbought |
| MACD Histogram | 0.36 | Bullish |
| vs SMA20 | 1.063x | Above |
| vs SMA50 | 1.138x | Above |
| vs SMA200 | 1.121x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $83.63
- **Stop Loss:** $80.05 (4.3% risk)
- **Target:** $89.00 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 279
- **Position Value:** $23,332.77
- **Portfolio %:** 23.33%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-04 (Est: $1.32)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.39 | +6.7% |
| 2025Q2 | $1.26 | $1.31 | +4.0% |
| 2025Q1 | $1.20 | $1.23 | +2.5% |
| 2024Q4 | $1.13 | $1.21 | +7.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*